Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Wedbush from $32.00 to $29.00 in a research note released on Monday, Benzinga reports. The firm currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $2.19 EPS and FY2027 earnings at $3.12 EPS. A […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low on Monday after Wedbush lowered their price target on the stock from $32.00 to $29.00. Wedbush currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $20.17 and last traded at $20.17, with a volume of 657271 shares […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $23.66, for a total value of $283,920.00. Following the completion of the sale, the insider now owns 1,053,313 shares of the […]
JPMorgan Chase & Co. lowered shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from an overweight rating to a neutral rating in a report released on Thursday morning, MarketBeat Ratings reports. JPMorgan Chase & Co. currently has $60.00 target price on the stock, down from their previous target price of $72.00. Other analysts have also […]
Bank of America cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a buy rating to a neutral rating in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. They currently have $40.00 target price on the stock, down from their previous target price of $114.00. APLS has been the subject […]